Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Beige mouse model for Mycobacterium avium complex disease.

Beige mouse model for Mycobacterium avium complex disease. Receive: RSS Feeds, eTOCs, free email alerts (when new articles cite this article), more» Information about commercial reprint orders: http://aac.asm.org/site/misc/reprints.xhtml To subscribe to to another ASM Journal go to: http://journals.asm.org/site/subscriptions/ ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Aug. 1995, p. 1647–1654 0066-4804/95/$04.00 0 Copyright 1995, American Society for Microbiology Vol. 39, No. 8 PATTISAPU R. J. GANGADHARAM Mycobacteriology Research Laboratories, Department of Medicine, University of Illinois at Chicago, Chicago, Illinois INTRODUCTION Mycobacterium avium complex (MAC), comprising M. avium, M. intracellulare, and M. scrofulaceum, has been recognized as an important group of organisms causing severe disease in humans, animals, and birds. Soon after AIDS was discovered, it was observed that MAC is also involved in that syndrome as a serious opportunistic infection and is associated with death within 6 to 12 months after diagnosis (12, 52). The clinical management of MAC disease has been difficult and frustrating, since these organisms are resistant to most of the antituberculosis drugs (98). Serious consideration was given to the discovery of effective agents that could be used to cure and prevent this disease, especially in AIDS patients. In the battery of investigations for the identification of new chemotherapeutic agents, in vivo tests with suitable animal models http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Antimicrobial Agents and Chemotherapy American Society For Microbiology

Beige mouse model for Mycobacterium avium complex disease.

Antimicrobial Agents and Chemotherapy , Volume volume 39 (issue 8) – Aug 1, 1995

Beige mouse model for Mycobacterium avium complex disease.

Antimicrobial Agents and Chemotherapy , Volume volume 39 (issue 8) – Aug 1, 1995

Abstract

Receive: RSS Feeds, eTOCs, free email alerts (when new articles cite this article), more» Information about commercial reprint orders: http://aac.asm.org/site/misc/reprints.xhtml To subscribe to to another ASM Journal go to: http://journals.asm.org/site/subscriptions/ ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Aug. 1995, p. 1647–1654 0066-4804/95/$04.00 0 Copyright 1995, American Society for Microbiology Vol. 39, No. 8 PATTISAPU R. J. GANGADHARAM Mycobacteriology Research Laboratories, Department of Medicine, University of Illinois at Chicago, Chicago, Illinois INTRODUCTION Mycobacterium avium complex (MAC), comprising M. avium, M. intracellulare, and M. scrofulaceum, has been recognized as an important group of organisms causing severe disease in humans, animals, and birds. Soon after AIDS was discovered, it was observed that MAC is also involved in that syndrome as a serious opportunistic infection and is associated with death within 6 to 12 months after diagnosis (12, 52). The clinical management of MAC disease has been difficult and frustrating, since these organisms are resistant to most of the antituberculosis drugs (98). Serious consideration was given to the discovery of effective agents that could be used to cure and prevent this disease, especially in AIDS patients. In the battery of investigations for the identification of new chemotherapeutic agents, in vivo tests with suitable animal models

Loading next page...
 
/lp/american-society-for-microbiology/beige-mouse-model-for-mycobacterium-avium-complex-disease-mfhdVbCVmZ

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
American Society For Microbiology
Copyright
Copyright © 1995 by the American society for Microbiology.
ISSN
0066-4804
eISSN
1098-6596
Publisher site
See Article on Publisher Site

Abstract

Receive: RSS Feeds, eTOCs, free email alerts (when new articles cite this article), more» Information about commercial reprint orders: http://aac.asm.org/site/misc/reprints.xhtml To subscribe to to another ASM Journal go to: http://journals.asm.org/site/subscriptions/ ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Aug. 1995, p. 1647–1654 0066-4804/95/$04.00 0 Copyright 1995, American Society for Microbiology Vol. 39, No. 8 PATTISAPU R. J. GANGADHARAM Mycobacteriology Research Laboratories, Department of Medicine, University of Illinois at Chicago, Chicago, Illinois INTRODUCTION Mycobacterium avium complex (MAC), comprising M. avium, M. intracellulare, and M. scrofulaceum, has been recognized as an important group of organisms causing severe disease in humans, animals, and birds. Soon after AIDS was discovered, it was observed that MAC is also involved in that syndrome as a serious opportunistic infection and is associated with death within 6 to 12 months after diagnosis (12, 52). The clinical management of MAC disease has been difficult and frustrating, since these organisms are resistant to most of the antituberculosis drugs (98). Serious consideration was given to the discovery of effective agents that could be used to cure and prevent this disease, especially in AIDS patients. In the battery of investigations for the identification of new chemotherapeutic agents, in vivo tests with suitable animal models

Journal

Antimicrobial Agents and ChemotherapyAmerican Society For Microbiology

Published: Aug 1, 1995

There are no references for this article.